Showing results (61-70 of 107) with videos related to
Sort By:
Pageof 11
International Immunopharmacology|October 25, 2011
Survivin expression and its potential clinical significance in gastrointestinal stromal sarcomaMeltem Baykara, Murat Akkus, Ramazan Yildiz, et al.Clinical Neurology and Neurosurgery|July 15, 2010
Radiation induced early necrosis in patients with malignant gliomas receiving temozolomideEmel Yaman, Suleyman Buyukberber, Mustafa Benekli, et al.Clinical Nuclear Medicine|October 14, 2010
Combination of preoperative ultrasonographic mapping and radioguided occult lesion localization in patients with locally recurrent/persistent papillary thyroid carcinoma: a practical method for central compartment reoperationsSeyfettin Ilgan, Erkan Oztürk, Ramazan Yildiz, et al.Journal of Cancer Research and Clinical Oncology|March 7, 2013
Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancerOnder Tonyali, Mustafa Benekli, Veli Berk, et al.Turkish Journal of Medical Sciences|May 30, 2024
Rasch analysis, reliability, and validity of the Turkish version of the Lumbar Spine Instability QuestionnaireErkan Erol, Umut Apaydin, Ramazan Yildiz, et al.Asian Pacific Journal of Cancer Prevention : APJCP|June 4, 2013
XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutionsKazim Uygun, Ahmet Bilici, Serap Kaya, et al.Oncotargets and Therapy|March 20, 2018
A national, multicenter, non-interventional, observational study on treatment patterns in patients with metastatic renal cell carcinoma in Turkey - NOTES studyŞuayib Yalçın, Ramazan Yildiz, Faysal Dane, et al.Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|December 24, 2014
Factors predicting recurrence in patients with grade III glial tumors: impact of adjuvant temozolomide on recurrenceOzge Gumusay, Bulent Cetin, Ahmet Ozet, et al.Journal of Cancer Research and Clinical Oncology|February 16, 2010
The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancerRamazan Yildiz, Mustafa Benekli, Suleyman Buyukberber, et al.Medical Oncology (Northwood, London, England)|May 20, 2008
Single agent gemcitabine in the second-line treatment of advanced non-small cell lung cancer after treatment with taxane + platinum regimensUgur Coskun, Ali Osman Kaya, Süleyman Buyukberber, et al.Pageof 11